
SNPHY
Healthcare · Drug Manufacturers - General · $4.08B market cap
$12.67+0.14 (+1.1%)Nov 13, 1:10 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 4, 2026 | Before the open | — | 0.16 | — |
| Nov 6, 2025 | Time not confirmed | — | 24.55 | — |
| Aug 4, 2025 | Before the open | — | 0.12 | — |
| May 13, 2025 | Time not confirmed | — | 25.69 | — |
| Feb 6, 2025 | Before the open | — | 0.17 | — |
| Nov 7, 2024 | Before the open | — | 0.16 | — |
| Aug 6, 2024 | Before the open | — | 0.19 | — |
| May 9, 2024 | Before the open | — | 0.00 | — |
| Feb 8, 2024 | Before the open | — | 0.14 | — |
| Sep 30, 2021 | Time not confirmed | — | 0.16 | — |
| Jun 30, 2021 | Time not confirmed | — | 0.17 | — |
| Mar 31, 2021 | Time not confirmed | — | -0.32 | — |
| Dec 31, 2020 | Time not confirmed | — | 0.18 | — |
| Aug 4, 2020 |
Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments. It products include Taflupro/Timolol maleate, a combination drug of a prostaglandin Fa…
| After the close |
| 16.90 |
| 15.49 |
| -8.3% |
| May 7, 2020 | After the close | — | 8.30 | — |
| Feb 3, 2020 | After the close | — | 17.92 | — |
| Nov 5, 2019 | After the close | — | 16.91 | — |
| Jul 31, 2019 | After the close | — | 16.03 | — |
| May 8, 2019 | After the close | — | 21.23 | — |
| Feb 4, 2019 | After the close | — | 22.10 | — |
| Nov 6, 2018 | After the close | — | 18.49 | — |
| Jul 31, 2018 | After the close | 22.60 | 16.85 | -25.4% |
| May 8, 2018 | After the close | — | 19.46 | — |
| Feb 5, 2018 | After the close | — | 29.71 | — |